Literature DB >> 24808435

Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up.

Soroush Rais-Bahrami1, Barış Türkbey, Ardeshir R Rastinehad, Annerleim Walton-Diaz, Anthony N Hoang, M Minhaj Siddiqui, Lambros Stamatakis, Hong Truong, Jeffrey W Nix, Srinivas Vourganti, Kinzya B Grant, Maria J Merino, Peter L Choyke, Peter A Pinto.   

Abstract

PURPOSE: We aimed to determine the natural history of small index lesions identified on multiparametric-magnetic resonance imaging (MP-MRI) of the prostate by evaluating lesion-specific pathology and growth on serial MP-MRI.
MATERIALS AND METHODS: We performed a retrospective review of 153 patients who underwent a minimum of two MP-MRI sessions, on an institutional review board-approved protocol. Index lesion is defined as the lesion(s) with the highest cancer suspicion score based on initial MP-MRI of a patient, irrespective of size. Two study cohorts were identified: (1) patients with no index lesion or index lesion(s) ≤7 mm and (2) a subset with no index lesion or index lesion(s) ≤5 mm. Pathological analysis of the index lesions was performed following magnetic resonance/ultrasound fusion-guided biopsy. Growth rate of the lesions was calculated based on MP-MRI follow-up.
RESULTS: Patients with small index lesions measuring ≤7 mm (n=42) or a subset with lesions ≤5 mm (n=20) demonstrated either benign findings (86.2% and 87.5%, respectively) or low grade Gleason 6 prostate cancer (13.8% and 12.5%, respectively) on lesion-specific targeted biopsies. These lesions demonstrated no significant change in size (P = 0.93 and P = 0.36) over a mean imaging period of 2.31±1.56 years and 2.40±1.77 years for ≤7 mm and ≤5 mm index lesion thresholds, respectively. These findings held true on subset analyses of patients who had a minimum of two-year interval follow-up with MP-MRI.
CONCLUSION: Small index lesions of the prostate are pathologically benign lesions or occasionally low-grade cancers. Slow growth rate of these small index lesions on serial MP-MRI suggests a surveillance interval of at least two years without significant change.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24808435      PMCID: PMC4463272          DOI: 10.5152/dir.2014.13319

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  21 in total

1.  A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.

Authors:  Tineke Wolters; Monique J Roobol; Pim J van Leeuwen; Roderick C N van den Bergh; Robert F Hoedemaeker; Geert J L H van Leenders; Fritz H Schröder; Theodorus H van der Kwast
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds.

Authors:  Baris Turkbey; Haresh Mani; Vijay Shah; Ardeshir R Rastinehad; Marcelino Bernardo; Thomas Pohida; Yuxi Pang; Dagane Daar; Compton Benjamin; Yolanda L McKinney; Hari Trivedi; Celene Chua; Gennady Bratslavsky; Joanna H Shih; W Marston Linehan; Maria J Merino; Peter L Choyke; Peter A Pinto
Journal:  J Urol       Date:  2011-09-25       Impact factor: 7.450

3.  Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-07-17       Impact factor: 25.391

4.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate.

Authors:  J E McNeal; A A Villers; E A Redwine; F S Freiha; T A Stamey
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

5.  D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging.

Authors:  Ardeshir R Rastinehad; Angelo A Baccala; Paul H Chung; Juan M Proano; Jochen Kruecker; Sheng Xu; Julia K Locklin; Baris Turkbey; Joanna Shih; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Pingkun Yan; Samuel Kadoury; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

6.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging.

Authors:  Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood
Journal:  J Urol       Date:  2011-08-17       Impact factor: 7.450

7.  Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation.

Authors:  Baris Turkbey; Peter A Pinto; Haresh Mani; Marcelino Bernardo; Yuxi Pang; Yolanda L McKinney; Kiranpreet Khurana; Gregory C Ravizzini; Paul S Albert; Maria J Merino; Peter L Choyke
Journal:  Radiology       Date:  2010-04       Impact factor: 11.105

8.  The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment.

Authors:  Bariş Türkbey; David Thomasson; Yuxi Pang; Marcelino Bernardo; Peter L Choyke
Journal:  Diagn Interv Radiol       Date:  2009-11-02       Impact factor: 2.630

9.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

10.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer.

Authors:  T A Stamey; F S Freiha; J E McNeal; E A Redwine; A S Whittemore; H P Schmid
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

View more
  24 in total

1.  The role of image guided biopsy targeting in patients with atypical small acinar proliferation.

Authors:  Dima Raskolnikov; Soroush Rais-Bahrami; Arvin K George; Baris Turkbey; Nabeel A Shakir; Chinonyerem Okoro; Jason T Rothwax; Annerleim Walton-Diaz; M Minhaj Siddiqui; Daniel Su; Lambros Stamatakis; Pingkun Yan; Jochen Kruecker; Sheng Xu; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2014-08-20       Impact factor: 7.450

2.  Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Authors:  Samrad Ghavimi; Hamidreza Abdi; Jennifer Waterhouse; Richard Savdie; Silvia Chang; Alison Harris; Lindsay Machan; Martin Gleave; Alan I So; Larry Goldenberg; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

3.  Perspective: a critical assessment of PI-RADS 2.1.

Authors:  T Ullrich; L Schimmöller
Journal:  Abdom Radiol (NY)       Date:  2020-12

4.  Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.

Authors:  R A Rakow-Penner; N S White; J K Parsons; H W Choi; M A Liss; J M Kuperman; N Schenker-Ahmed; H Bartsch; R F Mattrey; W G Bradley; A Shabaik; J Huang; D J A Margolis; S S Raman; L Marks; C J Kane; R E Reiter; D S Karow; A M Dale
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-06       Impact factor: 5.554

Review 5.  The role of MRI in active surveillance for prostate cancer.

Authors:  Michele Fascelli; Arvin K George; Thomas Frye; Baris Turkbey; Peter L Choyke; Peter A Pinto
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

Review 6.  Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer.

Authors:  Baris Turkbey; Anna M Brown; Sandeep Sankineni; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  CA Cancer J Clin       Date:  2015-11-23       Impact factor: 508.702

7.  Prostate diffusion imaging with distortion correction.

Authors:  Rebecca A Rakow-Penner; Nathan S White; Daniel J A Margolis; John Kellogg Parsons; Natalie Schenker-Ahmed; Joshua M Kuperman; Hauke Bartsch; Hyung W Choi; William G Bradley; Ahmed Shabaik; Jiaoti Huang; Michael A Liss; Leonard Marks; Christopher J Kane; Robert E Reiter; Steven S Raman; David S Karow; Anders M Dale
Journal:  Magn Reson Imaging       Date:  2015-07-26       Impact factor: 2.546

8.  MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men.

Authors:  Vidhush K Yarlagadda; Win Shun Lai; Jennifer B Gordetsky; Kristin K Porter; Jeffrey W Nix; John V Thomas; Soroush Rais-Bahrami
Journal:  Diagn Interv Radiol       Date:  2018 May-Jun       Impact factor: 2.630

9.  Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling.

Authors:  Raju Chelluri; Amichai Kilchevsky; Arvin K George; Abhinav Sidana; Thomas P Frye; Daniel Su; Michele Fascelli; Richard Ho; Steven F Abboud; Baris Turkbey; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto
Journal:  J Urol       Date:  2016-02-13       Impact factor: 7.450

10.  Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value.

Authors:  Ely R Felker; Jason Wu; Shyam Natarajan; Daniel J Margolis; Steven S Raman; Jiaoti Huang; Fred Dorey; Leonard S Marks
Journal:  J Urol       Date:  2015-12-07       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.